NICE Recommends OZURDEX(R), An Innovative Treatment For Retinal Vein Occlusion (RVO), A Common Cause Of Vision Loss
Allergan announces today that the National Institute for Health and Clinical Excellence (NICE) has recommended OZURDEX® (dexamethasone 0.7mg intravitreal implant in applicator) for the treatment of macular oedema due to central retinal vein occlusion (CRVO) and also for branch retinal vein occlusion (BRVO) where laser photocoagulation is neither beneficial nor appropriate...